



ASX & Media Release

## Patrys Releases New Video Explaining Applications of Deoxymab 3E10 Platform

**Melbourne, Australia; 20 March, 2019:** Patrys Limited (**ASX: PAB**), a therapeutic antibody development company announced today that it has released a follow up video that explains the generation of PAT-DX1 antibody, the smaller optimised form of Deoxymab 3E10 and the various applications available for this platform technology.

The video can be viewed via the Patrys website at: [www.patrys.com](http://www.patrys.com)

“In the last 12 months we have reported positive pre-clinical data from both *in vitro* and *in vivo* from both the PAT-DX1 and the PAT-DX1-NP programs, and this has continued to generate significant interest in these assets,” said Dr James Campbell, Chief Executive Officer and Managing Director of Patrys. “This video explains the generation of our lead candidate PAT-DX1, a di valent single-chain variable fragment antibody, and outlines some of the pre-clinical data generated so far. The video also highlights the excitement around this innovative and versatile technology platform both as a stand-alone therapeutic candidate and a tumor-targeting technology for conjugation to other molecules such as chemotherapy and radiation.”

### About Deoxymab 3E10, PAT-DX1 and PAT-DX1-NP

Deoxymab 3E10 is a DNA damage-repair (DDR) antibody that was first identified in lupus as an autoantibody that bound to normal cells. Of particular interest is that whilst most antibodies bind to cell surface markers, Deoxymab 3E10 penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes and kills cells that have mutations or deficiencies in DNA repair mechanisms as found in various cancer cells. Deoxymab 3E10 has single agent therapeutic potential and has been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further, Deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumors.

Patrys has developed a humanized form of Deoxymab 3E10, PAT-DX1 with improved activity over the original version of 3E10, and is progressing this, and a nanoparticle-conjugated form (PAT-DX1-NP) towards the clinic. In a range of pre-clinical cancer models PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumor explants and xenograft models. PAT-DX1 has also been shown to increase survival in mouse models of both triple negative breast cancer and glioblastoma. Patrys believes that PAT-DX1 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers. Patrys’ rights to Deoxymab 3E10 are part of a worldwide license to develop and commercialize as anti-cancer and diagnostic agents a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University.



**-Ends-**

**For further information, please contact:**

Patrys Limited:

James Campbell  
Chief Executive Officer  
P: +61 3 96703273  
[info@patrys.com](mailto:info@patrys.com)

Media and IR:

Kyahn Williamson  
Buchan Consulting  
P: +61 3 9866 4722  
[kwilliamson@we-buchan.com](mailto:kwilliamson@we-buchan.com)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).